FeesSafety
Pluang+

Biogen's Q3 sales rise on Alzheimer’s drug Leqembi, boosts 2026 EPS forecast

Company Fundamentals
20 Nov 2026, 20:43 WIB
Seeking Alpha
View Source
Bullish
Biogen's Q3 sales rise on Alzheimer’s drug Leqembi, boosts 2026 EPS forecast

Biogen reported a 10.7% year-over-year revenue increase to $2.8 billion in Q3, driven by strong sales of its Alzheimer’s drug Leqembi, which generated $202 million globally, up nearly 10% quarter-over-quarter. Leqembi also showed a 49% reduction in risk of Alzheimer’s progression, prompting Biogen to raise its 2026 non-GAAP EPS guidance. Despite broader market challenges, Biogen’s positive results and outlook support a continued buy rating.

As of Nov 21, 2026 02:02 WIB, Biogen Inc (BIIB) shares are trading at USD 249.97 on Pluang, showing a 1.15% gain in the last day despite all sell orders currently dominating at 100%. The stock holds a market cap of $36.53 billion and a typical hold time of 111 days among Pluang investors, highlighting steady interest even as the broader market experiences turmoil.

More News (BIIB)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App